Eugene was used to motivating others to be the best by giving their all. But when an ALS diagnosis knocked him to his knees, he rallied to find new ways to move forward. Learn about Eugene's game plan for living with ALS.
Search results for:
MN-166 (ibudilast) is an experimental oral therapy that’s designed to reduce inflammation and protect nerve cells from damage in people with ALS. Developed by MediciNova, it’s expected to slow disease progression.
Sponsored Content
A Caregiver’s ALS Journey of Courage and Support
When ALS impacted Rocío's husband Francisco, she knew the disease couldn't shake their greatest source of love and support—their family. Hear how they worked together to get Francisco the understanding and treatment he needed.
Neuvivo’s investigational therapy NP001 (sodium chlorite), designed to dampen inflammation and restore immune system balance, extended survival in people with amyotrophic lateral sclerosis (ALS), according to an combined analysis of data, spanning up to 11 years, on patients who took part in either of two Phase 2…
NeuroSense Therapeutics has initiated the process of applying to Canada’s regulators for early marketing approval of PrimeC in treating amyotrophic lateral sclerosis (ALS), based on positive findings in a Phase 2b clinical trial. The application will be filed under Health Canada’s Notice of Compliance with Conditions policy, which could…
A home-based multidisciplinary care model for people living with amyotrophic lateral sclerosis (ALS) was found feasible, and was rated as highly satisfactory by both patients and caregivers, according to a pilot study conducted in Germany. The care model also helped patients avoid hospitalizations and remain at home during the…
Sponsored Content
My Treatment Journey From Mexico to the US
When Francisco was diagnosed with ALS he knew it would be an uphill battle, but what he didn't know was the journey it would take him on. Discover how Francisco found the courage to move forward in the face of ALS.
Dewpoint Therapeutics has won a second grant from Target ALS Foundation to advance preclinical studies of its experimental TDP-43-targeted therapy for amyotrophic lateral sclerosis (ALS). TDP-43 is a protein that often gets mislocalized within cells in ALS and forms into toxic clumps that contribute to neurodegeneration. Dewpoint’s…
Treatment with a high dose of ILB, an experimental injection therapy being developed by Tikomed, was well tolerated and appeared to slow the progression of amyotrophic lateral sclerosis (ALS) in a small clinical trial in the U.K. That’s according to data from the exploratory Phase 2 study…
Sponsored Content
Finding a New Purpose in the Face of ALS
Being diagnosed with ALS felt like a crushing blow to Craig. As a former band director who mentored students, he knew his life would change. Discover how Craig found his new purpose and community to inspire.